statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gilead Sciences Unusual Options Activity

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy...

FDA Approves Biktarvy Label Update With Data for Pregnant Adults With HIV

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations. Gilead delivered another strong quarter of revenue growth in the first quarter with 6...

Gilead Sciences Announces First Quarter 2024 Financial Results

Key Events This Week: PCE, GDP, Fed Blackout And Earnings Gallore

 Hot on the heels of last week's tech and momentum rout, shaken traders will have to wait until Friday for the main...

Key Events This Week: PCE, GDP, Fed Blackout And Earnings Gallore

Latest Ratings for GILD
 DateFirmActionFromTo Mar 2022BarclaysMaintainsUnderweight Mar 2022RBC CapitalMaintainsOutperform Feb 2022BMO CapitalDowngradesOutperformMarket Perform
 View More Analyst...

The Analyst Verdict: Gilead Sciences In The Eyes Of 12 Experts

Biotech Innovations Paving the Way in Breast Cancer Fight Biotech Innovations Paving the Way in Breast Cancer Fight PR Newswire VANCOUVER, BC, April 11, 2024 FN Media Group Presents USA News Group...

Biotech Innovations Paving the Way in Breast Cancer Fight

, , . 52 . 52 . 3 350 . (NASDAQ:SBUX), (NASDAQ:GILD) SA (NYSE:ABEV) .
read more...

,    ,   52   :      ?

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25, 2024, after the market closes. At 4:30 p.m...

Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024

CENTRAL TRUST Co lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.2% during the fourth quarter, according to the company in its most recent filing with the...

CENTRAL TRUST Co Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences Inc (GILD) has been named as the ''Top Dividend Stock of the Nasdaq 100'', according to Dividend Channel, which published its most recent ''DividendRank'' report. The report noted...

GILD Named 'Top Dividend Stock of the Nasdaq 100' at Dividend Channel With 4.4% Yield

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Volume	12.38M
52-Wk High	$87.87
52-Wk Low	$64.63

GILD Gilead Sciences, Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals